The recombinant zoster vaccine is effective in preventing herpes zoster in adults aged 50 years or older with rheumatoid ...
The British pharmaceutical giant is working with the U.K. Dementia Research Institute to exploit a “natural randomization” ...
The study will analyse electronic health records of 65- and 66-year olds from the UK’s National Health Service (NHS).
Researchers have determined in a new study that the recombinant zoster vaccine (RZV) offers good protection from herpes ...
GSK takes advantage of natural experiment to study whether shingles vaccine can reduce dementia risk
After multiple studies have suggested a link between its shingles vaccine and dementia prevention, GSK is taking advantage of ...
GSK, UK Dementia Research Institute and Health Data Research UK to collaborate on first-of-its-kind dementia research initiative: London, UK Thursday, March 27, 2025, 09:00 Hrs [I ...
To test it prospectively, GSK will work with the UK Dementia Research Institute (UK DRI) and Health Data Research UK (HDR UK) ...
UK pharma major GSK (LSE: GSK) today announced a major new research collaboration with the UK Dementia Research Institute (UK ...
GSK (GSK) plc announced a new research collaboration with the UK Dementia Research Institute and Health Data Research UK to advance ...
Shingrix (zoster vaccine recombinant), could reduce the risk of dementia. The research plan follows multiple retrospective observational studies, which suggest a potential link between shingles ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback